Profil ADME dari Entitas Molekul Baru yang Disetujui oleh FDA Tahun 2021: Suatu Kajian In Silico

Ihsanul Arief, Hairunnisa Hairunnisa

Abstract


Aspek farmakokinetik dan farmakodinamik yang diwakili oleh sifat adsorpsi, distribusi, metabolisme, ekskresi (ADME) merupakan syarat penting suatu obat dapat menuju targetnya. Pada tahun 2021, food and drug administration (FDA) menyetujui 35 senyawa entitas molekul baru (EMB) untuk digunakan sebagai obat di masyarakat. Pada penelitian ini dikaji profil ADME dari senyawa-senyawa EMB tersebut yang meliputi kelarutan, GI absorption, BBB permeant, Lipinski rule of five, bioavailibility score dan synthetic accessibility. Struktur senyawa diperoleh dari basis data Pubchem dan kemudian dihitung profil ADME-nya melalui server SwissADME. Hasil yang diperoleh menunjukkan bahwa sebagian besar senyawa memenuhi persyaratan terkait sifat ADME terutama untuk obat-obat yang diadminitrasikan lewat oral.

Keywords


ADME, Lipinski rule of five, GI absorption, BBB permeant, bioavailability score

Full Text:

PDF

References


Ali, J., Camilleri, P., Brown, M. B., Hutt, A. J., & Kirton, S. B. (2012). Revisiting the general solubility equation: In silico prediction of aqueous solubility incorporating the effect of topographical polar surface area. Journal of Chemical Information and Modeling, 52(2), 420-428. https://doi.org/10.1021/ci200387c

Apgar, J. M., Wilkening, R. R., Parker, D. L., Meng, D., Wildonger, K. J., Sperbeck, D., Greenlee, M. L., Balkovec, J. M., Flattery, A. M., Abruzzo, G. K., Galgoci, A. M., Giacobbe, R. A., Gill, C. J., Hsu, M. J., Liberator, P., Misura, A. S., Motyl, M., Nielsen Kahn, J., Powles, M., "¦ Peel, M. (2021). Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorganic and Medicinal Chemistry Letters, 32(October 2020), 127661. https://doi.org/10.1016/j.bmcl.2020.127661

Arief, I., Pranowo, H. D., Mudasir, M., & Wijaya, K. (2020). QSAR-Based Design of Potent Betulinic Acid Derivatives as HIV Maturation Inhibitors. Chiang Mai University Journal of Natural Sciences, 20(1), e202110. https://doi.org/10.12982/CMUJNS.2021.010

Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021). U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. Journal of Medicinal Chemistry, 64(5), 2339-2381. https://doi.org/10.1021/acs.jmedchem.0c01786

Brown, D. G., & Wobst, H. J. (2021). A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. Journal of Medicinal Chemistry, 64(5), 2312-2338. https://doi.org/10.1021/acs.jmedchem.0c01516

Chagas, C. M., Moss, S., & Alisaraie, L. (2018). Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five. International Journal of Pharmaceutics, 549(1-2), 133-149. https://doi.org/10.1016/j.ijpharm.2018.07.046

Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717

Daina, A., & Zoete, V. (2016). A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem, 11(11), 1117-1121. https://doi.org/10.1002/cmdc.201600182

Deeks, E. D. (2021). Odevixibat: First Approval. Drugs, 81(15), 1781-1786. https://doi.org/10.1007/s40265-021-01594-y

Ertl, P., & Schuffenhauer, A. (2009). Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. Journal of Cheminformatics, 1(1), 1-11. https://doi.org/10.1186/1758-2946-1-8

Fukunishi, Y., Kurosawa, T., Mikami, Y., & Nakamura, H. (2014). Prediction of synthetic accessibility based on commercially available compound databases. Journal of Chemical Information and Modeling, 54(12), 3259-3267. https://doi.org/10.1021/ci500568d

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1-3), 3-25. https://doi.org/10.1016/S0169-409X(96)00423-1

Martin, Y. C. (2005). A Bioavailability Score. Journal of Medicinal Chemistry, 48(9), 3164-3170. https://doi.org/10.1021/jm0492002

Rasyid, H., Purwono, B., Hofer, T. S., & Pranowo, H. D. (2019). Hydrogen bond stability of quinazoline derivatives compounds in complex against EGFR using molecular dynamics simulation. Indonesian Journal of Chemistry, 19(2), 461-469. https://doi.org/10.22146/ijc.39567

Roskoski, R. (2020). Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research, 152(December 2019), 104609. https://doi.org/10.1016/j.phrs.2019.104609

Roskoski, R. (2021). Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological Research, 165(January), 105463. https://doi.org/10.1016/j.phrs.2021.105463

Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug Solubility: Importance and Enhancement Techniques. ISRN Pharmaceutics, 2012, 1-10. https://doi.org/10.5402/2012/195727




DOI: https://doi.org/10.34312/jambchem.v4i2.15257

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Jambura Journal of Chemistry



EDITORIAL OFFICE

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.